Page 133 - Read Online

Luo et al. Microbiome Res Rep 2025;4:10 https://dx.doi.org/10.20517/mrr.2024.57 Page 23 of 25

128. Lee JS, Poo H, Han DP, et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike
protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 2006;80:4079-87. DOI PubMed PMC
129. Xu YXY, Zhang XZ, Weng MM, et al. Oral immunization of mice with recombinant Lactobacillus plantarum expressing a
Trichinella spiralis galectin induces an immune protection against larval challenge. Parasit Vectors 2022;15:475. DOI PubMed
PMC
130. Zhang R, Peng X, Duan G, et al. An engineered Lactococcus lactis strain exerts significant immune responses through efficient
expression and delivery of Helicobacter pylori Lpp20 antigen. Biotechnol Lett 2016;38:2169-75. DOI
131. Zhang F, Ni L, Zhang Z, et al. Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal
immunity against H. pylori infection. Microb Cell Fact 2024;23:61. DOI PubMed PMC
132. Huynh DT, Chathuranga WAG, Chathuranga K, Lee JS, Kim CJ. Mucosal administration of Lactobacillus casei surface-displayed
HA1 induces protective immune responses against avian influenza A virus in mice. J Microbiol Biotechnol 2024;34:735-45. DOI
PubMed PMC
133. Sarnelli G, Del Re A, Palenca I, et al. Intranasal administration of Escherichia coli Nissle expressing the spike protein of SARS-CoV-
2 induces long-term immunization and prevents spike protein-mediated lung injury in mice. Biomed Pharmacother 2024;174:116441.
DOI
134. Zhao Z, Wang H, Zhang D, et al. Oral vaccination with recombinant Lactobacillus casei expressing Aeromonas hydrophila Aha1
against A. hydrophila infections in common carps. Virulence 2022;13:794-807. DOI PubMed PMC
135. Zhang Y, Yang L, Zhang J, et al. Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain
of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus. Microb Cell Fact 2022;21:185. DOI PubMed PMC
136. Qiao N, Du G, Zhong X, Sun X. Recombinant lactic acid bacteria as promising vectors for mucosal vaccination. Exploration
2021;1:20210026. DOI PubMed PMC
137. Guo S, Yan W, McDonough SP, et al. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore
challenge in a mouse model. Vaccine 2015;33:1586-95. DOI
138. Sarate PJ, Heinl S, Poiret S, et al. E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent
allergic poly-sensitization. Mucosal Immunol 2019;12:132-44. DOI
139. Rao S, Hu S, McHugh L, et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor
peptide. Proc Natl Acad Sci U S A 2005;102:11993-8. DOI PubMed PMC
140. Huang L, Tang W, He L, et al. Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A
virus in mice. Nat Commun 2024;15:6802. DOI PubMed PMC
141. Mohseni AH, Razavilar V, Keyvani H, Razavi MR, Khavari-Nejad RA. Oral immunization with recombinant Lactococcus lactis
NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice. J Med
Virol 2019;91:296-307. DOI PubMed
142. Li Y, Li X, Liu H, Zhuang S, Yang J, Zhang F. Intranasal immunization with recombinant Lactococci carrying human papillomavirus
E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice. Oncol Lett 2014;7:576-82. DOI
PubMed PMC
143. Benz I, Schmidt MA. Cloning and expression of an adhesin (AIDA-I) involved in diffuse adherence of enteropathogenic Escherichia
coli. Infect Immun 1989;57:1506-11. DOI PubMed PMC
144. Buddenborg C, Daudel D, Liebrecht S, Greune L, Humberg V, Schmidt MA. Development of a tripartite vector system for live oral
immunization using a gram-negative probiotic carrier. Int J Med Microbiol 2008;298:105-14. DOI PubMed
145. Sarnelli G, Del Re A, Pesce M, et al. Oral Immunization with Escherichia coli Nissle 1917 expressing SARS-CoV-2 spike protein
induces mucosal and systemic antibody responses in mice. Biomolecules 2023;13:569. DOI PubMed PMC
146. Remer KA, Bartrow M, Roeger B, Moll H, Sonnenborn U, Oelschlaeger TA. Split immune response after oral vaccination of mice
with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88. Int J Med Microbiol 2009;299:467-78. DOI
PubMed
147. Wen LJ, Hou XL, Wang GH, et al. Immunization with recombinant Lactobacillus casei strains producing K99, K88 fimbrial protein
protects mice against enterotoxigenic Escherichia coli. Vaccine 2012;30:3339-49. DOI
148. Huang Y, Lin X, Yu S, Chen R, Chen W. Intestinal engineered probiotics as living therapeutics: chassis selection, colonization
enhancement, gene circuit design, and biocontainment. ACS Synth Biol 2022;11:3134-53. DOI
149. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004;10:620-5.
DOI PubMed PMC
150. Yang M, Gu Y, Li L, et al. Bile acid-gut microbiota axis in inflammatory bowel disease: from bench to bedside. Nutrients
2021;13:3143. DOI PubMed PMC
151. Wang Y, Shi Y, Peng X, et al. Biochemotaxis-oriented engineering bacteria expressing GLP-1 enhance diabetes therapy by regulating
the balance of immune. Adv Healthc Mater 2024;13:e2303958. DOI
152. Hausmann O, Daha M, Longo N, et al. Pegvaliase: Immunological profile and recommendations for the clinical management of
hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy. Mol Genet Metab
2019;128:84-91. DOI
153. Mater DD, Langella P, Corthier G, Flores MJ. A probiotic Lactobacillus strain can acquire vancomycin resistance during digestive
transit in mice. J Mol Microbiol Biotechnol 2008;14:123-7. DOI PubMed